无码欧美成人av天堂456软件,大胆日本熟妇XXXX,9277在线观看免费播放,4p三个男人让我爽了一夜

產(chǎn)品訂購信息：
英文名稱  Anti-NFKB1/p50 

中文名稱   細(xì)胞核因子p50/k基因結(jié)合核因子抗體規(guī)格 

別    名  DKFZp686C01211; DNA binding factor KBF1; DNA binding factor KBF1 EBP1; DNA binding factor KBF1 EBP1; DNA-binding factor KBF1; EBP 1; EBP-1; EBP1; KBF1; MGC54151; NF kappa B; NF kappabeta; NF kB1; NFKB 1; NFKB p105; NFKB p50; NFKB1; NFKB1_HUMAN; Nuclear factor kappa B DNA binding subunit; Nuclear factor NF kappa B p105 subunit; Nuclear factor NF kappa B p50 subunit; Nuclear factor NF-kappa-B p50 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; p84/NF-kappa-B1 p98.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg 0.2ml/200μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Chicken, Dog, Pig, Cow 

產(chǎn)品類型   一抗  

研究領(lǐng)域     細(xì)胞生物 染色質(zhì)和核信號 信號轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學(xué)

蛋白分子量  predicted molecular weight: 48/105kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from NFKB1 (51-100aa) 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

細(xì)胞核因子p50/k基因結(jié)合核因子抗體規(guī)格 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009].

Function : NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.Subunit : Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator, which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID. Directly interacts with MEN1. Interacts with HIF1AN.Subcellular Location : Nucleus. Cytoplasm. Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).Post-translational modifications : While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.Polyubiquitination seems to allow p105 processing.S-nitrosylation of Cys-61 affects DNA binding.The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur as an alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.Similarity : Contains 7 ANK repeats.Contains 1 death domain.Contains 1 RHD (Rel-like) domain.Database links : UniProtKB/Swiss-Prot: P19838.2轉(zhuǎn)錄調(diào)節(jié)因子（Transcriptin Regulators）

Anti-CK17/FITC 熒光素標(biāo)記細(xì)胞角蛋白17抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-Integrin Beta5/FITC 熒光素標(biāo)記整合素β5抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh CCL4/MIP-1 Beta 巨噬細(xì)胞炎性蛋白1β抗體 規(guī)格 0.1ml

IL-2 (Interleukin-2)Human IL-2抗原(人) 0.5mg

HES3 英文名稱： 轉(zhuǎn)錄因子HES3抗體 0.2ml

Rhesus antibody Rh SP-C 肺表面活性蛋白C抗體 規(guī)格 0.1ml

Anti-Integrin Beta5/FITC 熒光素標(biāo)記整合素β5抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Mouse small nuclear ribonucleoprotein,snRNP/Sm ELISA Kit 小鼠抗小核糖核蛋白/Sm抗體Multi-class antibodies規(guī)格： 48T

Anti-phospho-Bim(Ser55) /FITC 熒光素標(biāo)記兔抗人、大、小鼠磷酸化細(xì)胞死亡調(diào)解子抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh ER-Alpha 雌激素受體α抗體 規(guī)格 0.1ml

apo-B100 (Rabbit apoprotein B100) ELISA Kit 兔載脂蛋白B100 96T

MMP-2 英文名稱： 基質(zhì)金屬蛋白酶2抗體 0.1ml

AE2 英文名稱： 陰離子交換蛋白2抗體 0.2ml

Anti-phospho-Bim(Ser55) /FITC 熒光素標(biāo)記兔抗人、大、小鼠磷酸化細(xì)胞死亡調(diào)解子抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-GRB10/FITC 熒光素標(biāo)記兔抗人、大、小鼠生長因子受體結(jié)合蛋白10抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-p300/KAT3B/FITC 熒光素標(biāo)記轉(zhuǎn)錄接頭蛋白EP300抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh beta-Actin (Loading Control) β-肌動蛋白抗體(內(nèi)參抗體) 規(guī)格 0.1ml

CD133 造血干細(xì)胞抗原CD133 0.5mg

phospho-HSP70 (Tyr611) 英文名稱： 磷酸化熱休克蛋白-70抗體 0.1ml

Rhesus antibody Rh RAP1GAP RAP1GAP酶激活蛋白抗體 規(guī)格 0.2ml

Anti-p300/KAT3B/FITC 熒光素標(biāo)記轉(zhuǎn)錄接頭蛋白EP300抗體IgGMulti-class antibodies規(guī)格： 0.2ml

牛津瓊脂基礎(chǔ)26060用于單核增生李斯特氏菌的選擇性分離(SN0005)。

GC 瓊脂基礎(chǔ) (CM0367) Oxoid incubation media GC 瓊脂基礎(chǔ) (CM0367) Oxoid

食酸菌 酸奶 支/瓶

VioletRedBileDextroseAgar

瓊脂培養(yǎng)基M 250g 于腸桿菌科細(xì)菌的生化反應(yīng)篩選。

改良的McBride瓊脂MMA26030250g用于單核細(xì)胞增生李斯特氏菌的選擇性分離培養(yǎng)(GB/T4789.30-2003，SN03)。

賴氨酸脫羧酶肉湯 (CM0308) Oxoid incubation media 賴氨酸脫羧酶肉湯 (CM0308) Oxoid

少根根霉 以正烷烴為碳源培養(yǎng)酵母，用此制成酵母膏和提取麥角固醇 支/瓶

大腸菌群、糞大腸菌群、大腸桿菌檢驗培養(yǎng)基

瓊脂培養(yǎng)基H 250g 用于腸道致病菌的選擇性分離培養(yǎng)。

細(xì)胞核因子p50/k基因結(jié)合核因子抗體規(guī)格 XLD瓊脂顆粒培養(yǎng)基  規(guī)格：  10袋（300mL/袋）  用途：  用于臨床標(biāo)本及食品中沙門氏菌、志賀氏菌的選擇性分離培養(yǎng)

營養(yǎng)肉湯顆粒培養(yǎng)基  規(guī)格：  10袋（300mL/袋）  用途：  用于一般細(xì)菌培養(yǎng)、復(fù)壯、增菌等，也可用于消毒劑定性消毒效果測定

大豆酪蛋白瓊脂顆粒培養(yǎng)基  規(guī)格：  10袋（300mL/袋）  用途：  用于普通的或營養(yǎng)要求較高的細(xì)菌以及用于醫(yī)藥工業(yè)潔凈室無菌程度的監(jiān)測及消毒劑效果的測試

平板計數(shù)瓊脂顆粒培養(yǎng)基  規(guī)格：  10袋（300mL/袋）  用途：  用于細(xì)菌總數(shù)測定

抗體的生物素化標(biāo)記實驗要點：

1. 細(xì)胞核因子p50/k基因結(jié)合核因子抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）細(xì)胞核因子p50/k基因結(jié)合核因子抗體規(guī)格 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。